Literature DB >> 7533684

Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection.

J F Tsai1, H S Margolis, J E Jeng, M S Ho, W Y Chang, Z Y Lin, J H Tsai.   

Abstract

Circulating immune complexes (CIC) may be involved in tissue damage and/or viral clearance in viral hepatitis. To assess the frequency of raised CIC in chronic hepatitis related to hepatitis B and C, IgM, IgG, and hepatitis B surface antigen (HBsAg) containing CIC were determined, by conglutinin (K) and C1q assays, in 101 patients with chronic hepatitis B alone, 24 patients with chronic hepatitis B and C, 48 patients with chronic hepatitis C alone, and 54 healthy controls. Compared to patients with hepatitis B alone, patients with dual infection had higher frequency of raised IgM-C1q CIC (P < 0.001) and IgM-K CIC (P < 0.01). There is no difference in the prevalence of HBsAg-CIC between patients with hepatitis B alone and those with dual infection. Among patients with chronic hepatitis C alone, conglutinin-binding CIC is the predominant type of raised CIC and correlated with more severe liver damage. In conclusion, CIC may play a role in the pathogenesis of chronic hepatitis C virus infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533684     DOI: 10.1006/clin.1995.1050

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

1.  Persistence of Circulating Hepatitis C Virus Antigens-Specific Immune Complexes in Patients with Resolved HCV Infection.

Authors:  Ke-Qin Hu; Wei Cui
Journal:  Dig Dis Sci       Date:  2018-03-08       Impact factor: 3.199

2.  Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection.

Authors:  Andreas Wieland; Rangaiah Shashidharamurthy; Alice O Kamphorst; Jin-Hwan Han; Rachael D Aubert; Biswa P Choudhury; Sean R Stowell; Junghwa Lee; George A Punkosdy; Mark J Shlomchik; Periasamy Selvaraj; Rafi Ahmed
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745

3.  Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases.

Authors:  J Miyaike; Y Iwasaki; A Takahashi; H Shimomura; H Taniguchi; N Koide; K Matsuura; T Ogura; K Tobe; T Tsuji
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

4.  Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

6.  Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

7.  Possible disease-modifying factors: the mannan-binding lectin pathway and infections in hereditary angioedema of children and adults.

Authors:  Maciej Cedzyński; Kazimierz Madaliński; Hanna Gregorek; Anna S Swierzko; Ewa Nowicka; Krystyna Obtułowicz; Katarzyna Dzierzanowska-Fangrat; Urszula Wojda; Daniel Rabczenko; Masaya Kawakami
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-02-05       Impact factor: 4.291

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.